CRL vs. RGEN: Charles River Laboratories vs. Repligen Stock Comparison
How do Charles River Laboratories (CRL) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Charles River Laboratories (CRL) and Repligen (RGEN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | CRL | RGEN |
|---|---|---|
| Name | Charles River Laboratories International, Inc. | Repligen Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 16.17 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 23, 2000 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | CRL | RGEN |
|---|---|---|
| Total Return (1Y) | 110.83% | 23.28% |
| Total Return (3Y, Annualized) | 27.87% | 6.20% |
| Total Return (5Y, Annualized) | -1.57% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | CRL | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 47.81% | 46.73% |
| Beta (5Y) | 1.33 | 1.11 |
| Max Drawdown (5Y) | -74.73% | -64.67% |
| Avg. Volume (3M) | 1.05M | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | CRL | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 2.23 | 0.41 |
| Sortino Ratio (1Y) | 3.58 | 0.60 |
Profitability
ROE (TTM)
Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Charles River Laboratories (CRL) reports 1.27%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.27%
- Max
- 109.18%
- Q3
- 6.23%
- CRL
- 1.27%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Charles River Laboratories (CRL) reports 1.01%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01%
- Max
- 18.05%
- Q3
- 4.78%
- CRL
- 1.01%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Charles River Laboratories (CRL) at 23.42% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.42%
- Max
- 83.12%
- CRL
- 23.42%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | CRL | RGEN |
|---|---|---|
| ROE (TTM) | 1.27% | -0.57% |
| ROA (TTM) | 4.74% | 1.40% |
| Net Margin (TTM) | 1.01% | -1.47% |
| Operating Margin (TTM) | 23.42% | 6.19% |
| Gross Margin (TTM) | 35.10% | 53.77% |
Growth
Revenue Growth
Repligen (RGEN) at 16.36% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.
Growth Metrics
| Metric | CRL | RGEN |
|---|---|---|
| Revenue Growth (YoY) | -0.85% | 16.36% |
| Revenue Growth (3Y CAGR) | 0.33% | -2.70% |
| EPS Growth (YoY) | -1,555.00% | -- |
| EPS Growth (3Y CAGR) | -- | -35.73% |
Financial Strength
Current Ratio (MRQ)
Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.41
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- CRL
- 1.41
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Repligen (RGEN) at 0.33 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 1.42
- CRL
- 0.87
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | CRL | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 1.41 | 9.88 |
| Debt / Equity (MRQ) | 0.87 | 0.33 |
| Net Debt / EBITDA | 2.92 | -1.19 |
Dividends
Dividend Yield (TTM)
Neither Charles River Laboratories (CRL) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Charles River Laboratories (CRL) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | CRL | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
366.87
- CRL
- 366.87
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
On P/S ratio, both Charles River Laboratories (CRL) at 4.07 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.07
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- CRL
- 4.07
- Q1
- 3.01
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Charles River Laboratories (CRL) at 5.01 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.01
- Max
- 13.53
- Q3
- 6.54
- CRL
- 5.01
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | CRL | RGEN |
|---|---|---|
| P/E Ratio (TTM) | 366.87 | -- |
| P/S Ratio (TTM) | 4.07 | 13.77 |
| P/B Ratio (MRQ) | 5.01 | 4.70 |
| Free Cash Flow Yield (TTM) | 2.74% | 1.01% |